AstraZeneca and Daiichi Sankyo share positive results from DESTINY-Lung02 phase 2 trial
Betsy Goodfellow | September 11, 2023 | News story | Medical Communications | AstraZeneca, Daiichi Sankyo, Enhertu, NSCLC, Oncology, clinical trial
AstraZeneca and Daiichi Sankyo have announced results from the primary analysis of the DESTINY-Lung02 phase 2 trial, which showed Enhertu’s (trastuzumab deruxtecan) continued strong and durable tumour responses in previously treated patients with HER2-mutant (HER2m) unresectable and/or metastatic non-squamous non-small cell lung cancer (NSCLC).
The drug has been developed collaboratively between AstraZeneca and Daiichi Sankyo.
The results were presented at the International Association for the Study of Lung Cancer (ASLC) 2023 World Conference on Lung Cancer (WCLC) as well as being published in the Journal of Clinical Oncology.
This analysis confirmed the objective response rate (ORR) as 49% and 56% in the 5.4mg/kg and 6.4mg/kg dosing groups respectively. The safety profile remains consistent with the established profile of the drug, however the 5.4mg/kg dose demonstrated a favourable safety profile for this indication.
Susan Galbraith, executive vice president of Oncology R&D at AstraZeneca, commented: “These results from DESTINY-Lung02 highlight that HER2 is an actionable target in lung cancer and reinforce the importance of testing for predictive biomarkers, including HER2 alterations, at the time of diagnosis to accurately identify patients who may be able to benefit from a targeted treatment. The data also reaffirm our belief in Enhertu as a potential new targeted treatment option for patients who have historically had limited options.”
Ken Takeshita, global head of R&D at Daiichi Sankyo, added: “The disease control achieved by more than 90% of patients with previously treated HER2-mutant non-small cell lung cancer in the primary analysis of DESTINY-Lung02 reinforces the efficacy we have already seen with Enhertu in this hard-to-treat disease. These results, along with encouraging progression-free survival and overall survival findings reported for the first time, demonstrate the potential role of Enhertu as an important treatment option for this patient population.”
Betsy Goodfellow
Related Content
AAX Biotech and Daiichi Sankyo partner to evaluate antibody therapeutics
AAX Biotech, a Swedish biotechnology company specialising in next-generation antibody therapeutics, has launched a strategic …
UCB announces first-in-patient trial success for galvokimig in atopic dermatitis
UCB has reported positive early clinical trial results for galvokimig, an investigational therapy for adults …
FDA approves Wegovy for treatment of MASH in adults with liver fibrosis
The US Food and Drug Administration (FDA) has granted accelerated approval for Wegovy (semaglutide) as …
